Princy Kumar
Infectious Disease · Washington, DCNPI 1790784957
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $180,241 of the $269,964 with a category attached, or 66.8%. 10 manufacturers reported payments, led by Merck at 38.7% of the total. Reporting peaked in 2019 at $65,525 and has fallen 57.5% since, to $27,877 in 2025. Among infectious disease clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $953.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$105K
- Viiv Healthcare Company$82K
- Gilead$38K
- Theratechnologies Inc.$19K
- Shionogi Inc$9K
- Amgen$6K
- plus $11K from 4 others
Across 578 payments — averaging $7320.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$945K
- Eli Lilly$645K
- Pfizer$588K
- Theratechnologies Inc.$571K
- Viiv Healthcare Company$535K
- Merck$438K
- plus $510K from 10 others
What the payments were for
- Royalty or licence$9300%
- Consulting fees$180,24167%
- Speaking & faculty fees$36,40013%
- Travel & lodging$46,88717%
- Food & beverage$5,4852%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 114 | $104,569 |
| Viiv Healthcare Company | 66 | $81,930 |
| Gilead | 45 | $38,345 |
| Theratechnologies Inc. | 19 | $18,886 |
| Shionogi Inc | 10 | $9,336 |
| Amgen | 2 | $5,531 |
| Janssen Scientific Affairs, LLC | 18 | $5,073 |
| Janssen Products, LP | 4 | $3,010 |
| Aimmune Therapeutics, Inc. | 1 | $3,000 |
| GSK | 4 | $285 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$269,964 in reported general payments places this provider in the 95th percentile of 74 infectious disease providers in District of Columbia.
See all infectious disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 35 | $181,832 |
| DescovyEmtricitabine/Tenofov Alafenam | 50 | $128,763 |
| JulucaDolutegravir/Rilpivirine | 39 | $127,344 |
| TivicayDolutegravir Sodium | 48 | $124,385 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 17 | $113,069 |
| PrezcobixDarunavir/Cobicistat | 21 | $52,822 |
| CompleraEmtricita/Rilpivirine/Tenof Df | 11 | $39,214 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $34,931 |
| IsentressRaltegravir Potassium | 13 | $24,942 |
| Testosterone | 11 | $500 |
| Chlorthalidone | 13 | $106 |
| Atorvastatin Calcium | 19 | $77 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $75 |
| Allopurinol | 14 | $54 |
| Lisinopril | 15 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyJuluca, Tivicay, Triumeq, Dovato | $81,930 | $399,728116 claims |
| GileadBiktarvy, Descovy | $38,345 | $310,59585 claims |
| MerckIsentress | $104,569 | $24,94213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 74 infectious disease providers in District of Columbia.
Other infectious disease in Washington
- Jesse GoodmanWashington$1.8M
- Theo HodgeWashington$1M
- Robert GasserWashington$922K
- Jose ChavezWashington$254K
- Linda NabhaWashington$60K
- Gebeyehu TeferiWashington$25K
- Jose BordonWashington$12K
- Rebecca KumarWashington$12K
- Jeffrey MurrayWashington$8K
- David DiemertWashington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.